EGFR and non-small cell lung carcinoma: In this comprehensive nationwide study, we demonstrated that both the mOS and the long-term survival of real-world patients with advanced EGFR- and ALK negative NSCLC, treated with systemic antineoplastic treatment, has improved since the implementation of ICIs in Denmark.